Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
Tóm tắt
Từ khóa
Tài liệu tham khảo
Arvela P, Kirjarinta M, Kirjarinta M, Kärki N, Pelkonen O (1988) Polymorphism of debrisoquine hydroxylation among Finns and Lapps. Br J Clin Pharmacol 26: 601?603
Bechtel P, Joanne C, Bechtel Y, Grandmottet M, Jounet JM (1986) Stabilité et/ou variabilité l'expression du polymorphisme génétique d'hydroxylation et d'acetylation chez de malades présentant des pathologies et soumis à des thérapeutiques variées. Ann Biol Clin 44: 361?367
Benitez J, Llerena A, Cobaleda J (1988) Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther 44: 74?77
Bertilsson L (1989) Ethnic differences in drug disposition. In: Breimer DD, Crommelin DJA, Midha KK (eds) Topics in Pharmaceutical Sciences. 1989. Amsterdam, Medical Press
Breimer DD, Schellens JHM, Soons PA (1988) Assessment of in vivo oxidative drug metabolizing enzyme activity in man by applying a cocktail approach. In: Miners J, Birkett DJ, Drew R, McManus M (eds) Proceedings of the VIIth International Symposium on Microsomes and Drug Oxidations (Adelaide, August 17?21, 1987) pp 232?240. Taylor and Francis, London
Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537?547
Brøsen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 57: 357?360
Drøhse A, Bathum L, Brøsen K, Gram LF (1989) Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 27: 620?625
Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C (1986) The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 22: 49?53
Eichelbaum M, Spannbrucker N, Dengler HJ (1975) N-Oxidation of sparteine in man and its interindividual differences. Naunyn Schmiedebergs Arch Pharmacol 287 (Suppl): R94 (Proceedings)
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183?187
Emery AEH (1986) Methodology in Medical Genetics. Churchill Livingstone, p 5
Evans DAP, Manley KA, McKusick VA (1960) Genetic control of isoniazid metabolism in man. Br Med J 2: 485?491
Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102?105
Gachályi B, Róna K, Vas A, Káldor A (1986) A debrisoquin hydroxiláció polimorfizmusának vizsgálata. Orvosi Hetilap 127: 2299?2301
Harris H, Hopkinson DA, Luffman J (1968) Enzyme diversity in human populations. Ann NY Acad Sci 151: 232?242
Inaba T, Vinks A, Otton SV, Kalow W (1983) Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther 33: 394?399
Iyun AO, Lennard MS, Tucker GT, Woods HF (1986) Metoprolol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 40: 387?394
Jackson PR, Tucker GT, Lennard MS, Woods HF (1986) Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 22: 541?550
Jacqz E, Dulac H, Mathieu H (1988) Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 35: 167?171
Küpfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753?759
Larrey D, Amouyal G, Tinel M, Letteron P, Berson A, Labbe G, Pessayre D (1987) Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol 24: 676?679
Leclercq V, Desager JP, van Nieuwenhuyze Y, Harvengt C (1987) Prevalence of drug hydroxylator phenotypes in Belgium. Eur J Clin Pharmacol 33: 439?440
Leopold G (1986) Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 8 [Suppl 11]: 16?20
Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II: 584?586
McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF (1985) Metoprolol metabolism and debrisoquine oxidation polymorphism ? population and family studies. Br J Clin Pharmacol 20: 555?566
Paar WD, Schuhler H, Fimmers R, Dengler HJ (1989) Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma. Eur J Clin Pharmacol 36: 555?560
Sanz EJ, Villén T, Alm C, Bertilsson L (1989) S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 45: 495?499
Schellens JHM, Danhof M, Breimer DD (1986) The poor metabolizer incidence of sparteine, mephenytoin and nifedipine in a Dutch population. Acta Pharmacol Toxicol 59 [Suppl V]: 252
Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38: 618?624
Skoda RC, Gonzalez FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P-450dbl gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci 85: 5240?5243
Steiner E, Alván G, Garle M, Maguire JH, Lind M, Nilson SO, Tomson T, McClanahan JS, SjÖqvist F (1987) The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin. Clin Pharmacol Ther 42: 326?333
Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F (1988) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44: 431?435
Steiner E, Iselius L, Alván G, Lindsten J, Sjöqvist F (1985) A family study of genetic and environmental factors influencing polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 38: 394?492
Syvälahti EKG, Lindberg R, Kallio J, de Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22: 89?92
Vogel F, Motulsky AG (eds) (1986) Human Genetics. Springer, Berlin, Heidelberg, New York
Woolhouse NM, Eichelbaum M, Oates NS, Idle JR, Smith RL (1985) Dissociation of coregulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 37: 374?378